adc

Biointron is excited to announce our participation in World ADC USA 2025, a leading event dedicated to accelerating the development of antibody-drug conjugates (ADCs). Taking place in San Diego, CA, from November 3-6, 2025, this conference brings together industry experts, researchers, and innovators to explore the latest advancements in ADC technology, clinical progress, and manufacturing solutions.

Biointron is excited to announce our participation in World ADC Asia 2025, set to take place in Incheon, South Korea, from June 10-12, 2025. This premier event is dedicated to accelerating the development of antibody-drug conjugates (ADCs), uniting experts from across the biopharmaceutical industry to share insights, showcase innovations, and drive forward the future of targeted therapeutics.

This January, top news includes glycoengineering, anti-malarial antibodies, and PROTACs.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

ADCs are reshaping biopharma. Biointron explores how antibody-drug conjugates combine precision targeting with potent payloads to transform therapies.

Biointron is excited to announce our participation in the World ADC London 2025 Conference, set to take place March 3-6, 2025, in London, UK.

Microtubule inhibitors power certain ADCs. Biointron highlights how these payloads, combined with antibodies, deliver targeted cancer therapies.

ADCC directs immune cells to kill targets. Biointron explains how this mechanism underpins therapeutic antibody efficacy in oncology and virology.

ADCs unite antibody targeting with potent payloads. Biointron explains their mechanisms and importance in advancing cancer therapeutics.

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

ADCs have evolved into powerful cancer drugs. Biointron reviews their history, design improvements, and future directions in targeted therapy.

DAR is key to ADC success. Biointron explains how drug-to-antibody ratios shape potency, safety, and outcomes in cancer therapy.

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

ADCs and checkpoint inhibitors create synergy in oncology. Biointron explains how combining these modalities improves precision and patient outcomes.

Antibody drug development has revolutionized biomedicine. Biointron highlights stages from discovery to approval that shape antibody-based therapies.